Deoxyribonucleic Acid (DNA) Vaccines Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Deoxyribonucleic Acid (DNA) Vaccines Market Trends and Insights

Faster Response to Emerging and Re-emerging Pathogens

DNA vaccines can use a validated plasmid backbone with a newly selected antigen sequence, which can shorten the early design stage after a pathogen is genetically characterized. INOVIO moved from sequence selection to a first human dose in 82 days during the COVID-19 response. The INO-4500 Phase 1b study in 220 adults in Ghana reported measurable humoral and cellular responses after intradermal administration with electroporation.^{[1]Smiley, C. et al., “Safety, Tolerability, and Immunogenicity of INO-4500, a Synthetic DNA-Based Vaccine Against Lassa Virus, in a Phase 1b Clinical Trial in Healthy Ghanaian Adults,” Frontiers in Immunology, frontiersin.org} This result supports continued development against pathogens such as the Lassa virus, where a rapid response platform may have practical value. The DNA vaccines market can also benefit when preparedness programs create reusable manufacturing and regulatory experience before an outbreak requires broad deployment. Lower temperature sensitivity than many mRNA products can further support use in areas with constrained cold-chain infrastructure.

Growing Therapeutic Oncology and Personalized Vaccine Pipelines

Therapeutic DNA vaccines are being developed to direct immune responses against tumor-specific mutations rather than to prevent an infection. A 2026 Phase 1 glioblastoma study reported vaccine-specific T-cell responses from a personalized DNA vaccine that targeted up to 40 spatially distributed neoantigens.^{[2]Chiriboga, F. et al., “Adjuvant Personalized Multivalent Neoantigen DNA Vaccination for MGMT Unmethylated Glioblastoma: A Phase 1 Trial,” Nature Cancer, nature.com} Research on neoantigen vaccines has also described the potential for durable T-cell immunity, although clinical benefit must be assessed in each program. Touchlight reported first patient dosing in the NEOVACC Phase I personalized lung cancer vaccine trial in July 2026 using its cell-free dbDNA platform.^{[3]Touchlight Genetics, “Touchlight’s dbDNA Manufacturing Facility Receives World-First GMP License from MHRA,” Touchlight, touchlight.com} Faster production may make patient-specific products more workable for tumors that progress quickly. This activity supports the 9.2% forecast CAGR for oncology within the DNA vaccines market.

Greater Demand for Stable, Scalable Vaccine Platforms

DNA vaccines in lyophilized form can remain stable under standard refrigeration, reducing the distribution burden for some programs. Cell-free production methods from Touchlight and LineaRx are designed to avoid bacterial fermentation and to shorten manufacturing cycles. Entos announced a USD 198.5 million partnership with the governments of Canada and Alberta in March 2025 to build an Edmonton facility designed for research and GMP manufacturing. The facility is planned to support the production of 10 million vaccine doses per year. Touchlight stated that its Hampton site has 11 manufacturing suites and an annual capacity of above 8 kg of DNA. These investments indicate that the DNA vaccines market is building supply capacity before large human product launches occur.

Expansion of Veterinary and Zoonotic Disease Prevention

Animal DNA vaccines provide a commercial record for a platform that is still seeking wider human adoption. Existing use in companion animals, horses, and aquaculture has created regulatory and manufacturing familiarity. The overlap between animal and human pathogen risks can also support funding for zoonotic disease programs. A 2025 study found that a lipid nanoparticle DNA vaccine against canine distemper generated neutralizing antibodies for more than 300 days in dogs. Touchlight and Ceva Animal Health entered a multi-year arrangement to develop and manufacture dbDNA animal health vaccines. Such agreements show that animal health can remain a revenue source and a practical development setting for the DNA vaccines market.

Lower Human Immunogenicity With Conventional Injection

Conventional intramuscular and subcutaneous injection has produced weaker immune responses for many human DNA vaccine candidates. Published clinical data have indicated that measurable responses may require a 2 mg DNA dose, compared with 30 to 100 μg doses for mRNA COVID-19 vaccines. DNA must reach the cell nucleus, and ordinary injection does not assist this process. Electroporation can improve cellular uptake, but it adds equipment and administration requirements. A 2025 preclinical study reported durable protection in mice after an LNP-formulated H5N1 plasmid DNA vaccine. LNP formulation may reduce this limitation, but it still requires clinical validation and a scalable manufacturing process for human programs.

Limited Human Commercial Validation and Reimbursement Precedent

The absence of an FDA-approved commercial human DNA vaccine leaves pricing, coverage, and formulary practices unsettled. INOVIO's BLA for INO-3107 is under FDA review with a target action date of October 30, 2026. The company reported that 81% of Phase 1/2 participants needed fewer surgeries after treatment than in the prior year. An orphan product approval would be important, but it would not automatically establish reimbursement practice for every DNA medicine. ZyCoV-D also showed that a product can reach the market after the peak of an acute public-health need, which can limit adoption. Developers in the DNA vaccines market will need to align clinical development, launch timing, and payer evidence with active disease burden.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Type: Human Programs Lead Revenue While Animal Products Provide Commercial Experience

Human DNA vaccines accounted for 61.83% of revenue in 2025. This position reflects clinical activity in HPV-related disease, infectious diseases, and oncology. The human segment includes programs for MERS-CoV, Lassa virus, Ebola, influenza, and cancer. Animal vaccines supplied the remaining revenue and remain the source of fully commercialized product experience for the platform. Products for canine melanoma, equine disease, and salmon aquaculture have provided a reference point for manufacturing and regulatory practice. This history helps developers explain how DNA-based products can be made and administered.

Human DNA vaccines are forecast to grow at an 8.51% CAGR from 2026 to 2031. VGX-3100 reported positive topline results from its China Phase III study in May 2026, including 207 participants at 22 tertiary hospitals and achievement of the primary endpoint. Fosun Wanbang obtained Greater China commercialization rights in January 2026 under a deal valued at CNY 800 million, equivalent to USD 113 million, in upfront and milestone payments plus double-digit royalties. These terms provide a useful commercial reference for the human DNA vaccines market in Asia-Pacific. Animal programs can move through shorter development pathways and face different evidence requirements. They are likely to remain an important near-term contributor while human products mature.

By Vaccine Purpose: Therapeutic Candidates Are Expanding Faster Than Prophylactic Programs

Prophylactic vaccines accounted for 65.38% of revenue in 2025. Pandemic preparedness, infectious disease prevention, and the established animal health base supported that position. Therapeutic programs are forecast to grow at a 9.07% CAGR through 2031. Their growth is tied mainly to oncology programs that seek to stimulate responses against neoantigens. This use differs from prevention because each patient may need a distinct construct. It also creates different demands for manufacturing turnaround and clinical evidence.

Personalized therapeutic vaccines often require manufacturing from biopsy material to a finished dose in less than 4 weeks. The NEOVACC trial demonstrates how cell-free production is being used to address this operational need. Therapeutic programs for allergy and autoimmune disease remain early in development. The available input also identifies patient selection as a key issue for non-small cell lung cancer. Companion diagnostics could therefore be needed before therapeutic vaccines gain broad use. The DNA vaccines industry may see a higher-value product mix if oncology candidates establish meaningful clinical benefit. That opportunity still depends on response prediction, manufacturing consistency, and payer acceptance.

By Technology Platform: Plasmid DNA Retains the Largest Base as Cell-Free Formats Develop

Plasmid DNA held 72.16% of the technology platform segment in 2025. Its share reflects established cGMP experience across bacterial fermentation-based manufacturing networks. Developers know the process expectations for plasmid products entering later clinical stages. Plasmid DNA is also forecast to grow at a 9.18% CAGR through 2031. The growth rate reflects the volume of clinical programs, especially in oncology and infectious diseases. It does not remove the need to improve delivery and simplify manufacturing.

Linear DNA and minicircle DNA are being developed as alternatives to conventional plasmids. They can address concerns related to antibiotic resistance markers and bacterial fermentation artifacts. Touchlight received an MHRA GMP license for cell-free dbDNA manufacturing in January 2025. Applied DNA Sciences completed its LineaDNA GMP facility buildout in January 2025. These platforms may give developers more manufacturing options as programs move into later studies. MIDGE vectors and DNA origami platforms remain preclinical and add to the longer-term technology range.

By Delivery Method: Electroporation Leads Today While Lipid Nanoparticles Grow Faster

Electroporation held 55.63% of delivery method revenue in 2025. Its position reflects clinical use with INOVIO's CELLECTRA platform and Ichor Medical Systems' TriGrid system. The method temporarily permeabilizes cell membranes to increase DNA uptake. A review available through the National Institutes of Health reported that electroporation can raise responses by 10 to 1,000 times relative to ordinary injection. PharmaJet's Tropis system also supports needle-free intradermal delivery for ZyCoV-D. Suction-based systems and liposome or polymer approaches serve smaller veterinary and early research uses.

Lipid and nanoparticle delivery is forecast to grow at an 8.82% CAGR through 2031. A 2024 study found stronger HPV-specific cellular responses in mice using SM-102 lipid nanoparticles than with electroporation, while naked plasmid injection showed minimal response. LNP approaches could allow administration without specialized electroporation equipment. This could widen the delivery setting from specialist centers to ordinary clinics. Ionizable lipids can also support immune activation and may reduce the dose requirement. Clinical performance in humans will determine whether this delivery shift changes the DNA vaccines market more broadly.

By Route of Administration: Intradermal Delivery Holds Both Scale and Growth

Intradermal administration accounted for 48.63% of the route segment in 2025. It is also forecast to grow at a 9.87% CAGR through 2031. The skin contains Langerhans cells and dermal dendritic cells that can support immune activation. INOVIO's CELLECTRA 2000 is optimized for intradermal electroporation in active programs. ZyCoV-D also uses PharmaJet's Tropis intradermal needle-free system. These examples support intradermal delivery as an established route for DNA vaccine candidates.

Intramuscular administration remains familiar for biologic products and is relevant for LNP-based DNA vaccines. LNP products are commonly given intramuscularly in the mRNA setting. Subcutaneous delivery has a role in selected animal health programs. Oral and mucosal approaches remain preclinical and are not near-term commercial drivers. A move from electroporation to LNP delivery could allow intramuscular administration to regain share. The final route mix will depend on formulation results and the settings where products can be administered.

By Indication: Infectious Diseases Lead While Oncology Has the Highest Growth Rate

Infectious diseases accounted for 38.63% of indication revenue in 2025. This segment includes COVID-19, HPV-related disease, Zika virus, MERS-CoV, influenza, and other pathogens. HPV-related programs are among the most advanced. INO-3107 is under FDA BLA review for recurrent respiratory papillomatosis. INO-4700 completed a Phase 2a study across 0.6 mg, 1 mg, and 2 mg dose levels, with findings on safety and immunogenicity published in 2025. Earlier programs on the Zika virus and influenza add breadth to the infectious disease base.

Oncology is forecast to grow at a 9.21% CAGR through 2031. Active programs cover glioblastoma, HPV-positive oropharyngeal cancer, non-small cell lung cancer, and cervical cancer. AACR 2026 data from the VB-C-03 trial reported measurable immunogenicity for VB10.16 with pembrolizumab in first-line HPV16-positive oropharyngeal cancer. Combination treatment with checkpoint inhibitors is, therefore, a central clinical approach for oncology DNA vaccine candidates. Veterinary diseases remain a distinct, commercially relevant indication group. Allergies and autoimmune conditions are earlier opportunities that may grow if T-cell modulation is validated in larger studies.

By End User: Hospitals Lead Delivery While Veterinary Clinics Expand Faster

Hospitals and clinics accounted for 61.32% of end-user revenue in 2025. Current human programs often need electroporation equipment and trained staff. This makes institutional settings the practical delivery location for many candidates. Research institutes and academic centers remain important even if their direct revenue is lower. The Clatterbridge Cancer Centre, the Wistar Institute, and the University of Liverpool contribute early-stage work that supports future commercial programs. NEOVACC at Clatterbridge is a current example of this research role.

Veterinary hospitals and clinics are forecast to grow at an 8.35% CAGR through 2031. This reflects approved animal products and new collaborations between platform companies and animal health businesses. Government and public-health buyers can support preparedness procurement and national immunization work. Pharmaceutical and biotechnology companies also buy plasmid manufacturing services while developing proprietary candidates. This overlap can create closer links between CDMOs and product developers. The DNA vaccines industry is therefore likely to see more vertical integration as manufacturing capacity becomes a competitive requirement.

Geography Analysis

North America held 38.12% of the global DNA vaccines market in 2025. The region has a high concentration of clinical developers, plasmid CDMOs, and delivery technology suppliers. Canada and Alberta committed USD 198.5 million to Entos Pharmaceuticals' Edmonton manufacturing project in 2025. The planned site targets a capacity of 10 million vaccine doses per year. In the United States, INOVIO reported that pre-licensure inspections for INO-3107 were complete in its second-quarter 2026 update. Mexico remains a smaller participant, with activity centered on government health procurement rather than domestic product development.

Europe is the second-largest regional market. The MHRA granted the first GMP license for cell-free enzymatic DNA production to Touchlight's Hampton facility in January 2025. INO-3107 has an EMA Orphan Drug designation and a UK Innovation Passport under the ILAP pathway. Germany, France, and Italy have established biologics manufacturing capabilities. NorthX Biologics is supporting Amarna Therapeutics as it prepares Nimvec AM510 for first-in-human studies expected by 2027. European developers and academic groups add to the region's clinical and manufacturing depth.

Asia-Pacific is forecast to grow at an 8.76% CAGR from 2026 to 2031. India established a key precedent through ZyCoV-D, the first approved human plasmid DNA vaccine, under the National Biopharma Mission. China adds momentum through VGX-3100 Phase III results and Fosun Wanbang's Greater China commercialization arrangement. Japan, Australia, and South Korea contribute to pipeline and clinical trial activity. The Middle East, Africa, and South America remain smaller markets. Thermal stability can support a longer-term opportunity in these locations as public-health systems expand.